title: P2X7 receptors in neurohypophysial terminals: evidence for their role in arginine-vasopressin secretion.
abstract: Arginine-vasopressin (AVP) plays a major role in maintaining cardiovascular function and related pathologies. The mechanism involved in its release into the circulation is complex and highly regulated. Recent work has implicated the purinergic receptor, P2X7R, in a role for catecholamine-enhanced AVP release in the rat hypothalamic-neurohypophysial (NH) system. However, the site of P2X7R action in this endocrine system, and whether or not it directly mediates release in secretory neurons have not been determined. We hypothesized that the P2X7R is expressed and mediates AVP release in NH terminals. P2X7R function was first examined by patch-clamp recordings in isolated NH terminals. Results revealed that subpopulations of isolated terminals displayed either high ATP-sensitivity or low ATP-sensitivity, the latter of which was characteristic of the rat P2X7R. Additional recordings showed that terminals showing sensitivity to the P2X7R-selective agonist, BzATP, were further inhibited by P2X7R selective antagonists, AZ10606120 and brilliant blue-G. In confocal micrographs from tissue sections and isolated terminals of the NH P2X7R-immunoreactivity was found to be localized in plasma membranes. Lastly, the role of P2X7R on AVP release was tested. Our results showed that BzATP evoked sustained AVP release in NH terminals, which was inhibited by AZ10606120. Taken together, our data lead us to conclude that the P2X7R is expressed in NH terminals and corroborates its role in AVP secretion.
authors.affiliation: Department of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, Massachusetts.
authors.forename: Adolfo E
authors.initials: AE
authors.lastname: Cuadra
authors.forename: Edward E
authors.initials: EE
authors.lastname: Custer
authors.forename: Elizabeth L
authors.initials: EL
authors.lastname: Bosworth
authors.forename: José R
authors.initials: JR
authors.lastname: Lemos
mesh_terms: D000255:Adenosine Triphosphate / Q000031:analogs & derivatives / Q000378:metabolism / Q000494:pharmacology; D000818:Animals; D001127:Arginine Vasopressin / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D008297:Male; D008564:Membrane Potentials; D010904:Pituitary Gland, Posterior / Q000187:drug effects / Q000378:metabolism*; D017729:Presynaptic Terminals / Q000187:drug effects / Q000378:metabolism*; D058911:Purinergic P2X Receptor Agonists / Q000494:pharmacology; D058920:Purinergic P2X Receptor Antagonists / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D058486:Receptors, Purinergic P2X7 / Q000187:drug effects / Q000378:metabolism*; D013997:Time Factors
chemical_list: D058911:Purinergic P2X Receptor Agonists; D058920:Purinergic P2X Receptor Antagonists; D058486:Receptors, Purinergic P2X7; D001127:Arginine Vasopressin; C033901:3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate; D000255:Adenosine Triphosphate
references.citation: J Physiol. 2012 May 15;590(10):2285-304
references.pmid: 22411013
references.citation: J Exp Biol. 1986 Sep;124:53-72
references.pmid: 2428909
references.citation: Pharmacol Ther. 2004 Oct;104(1):29-45
references.pmid: 15500907
references.citation: J Biol Chem. 2001 Jun 29;276(26):23262-7
references.pmid: 11313357
references.citation: Endocrinology. 2011 Jun;152(6):2342-52
references.pmid: 21467198
references.citation: J Cell Physiol. 2008 Oct;217(1):155-61
references.pmid: 18481265
references.citation: Clin Auton Res. 2005 Aug;15(4):254-63
references.pmid: 16032381
references.citation: Annu Rev Pharmacol Toxicol. 2000;40:563-80
references.pmid: 10836147
references.citation: J Physiol. 1990 Mar;422:321-31
references.pmid: 2352182
references.citation: Neuroscience. 1982;7(11):2867-72
references.pmid: 6296723
references.citation: J Physiol. 1999 Jan 15;514 ( Pt 2):351-67
references.pmid: 9852319
references.citation: Eur J Pharmacol. 2011 Oct 15;668(3):366-72
references.pmid: 21819977
references.citation: Neuroscience. 1982;7(11):2873-81
references.pmid: 6296724
references.citation: Brain Res Rev. 2007 Nov;56(1):119-47
references.pmid: 17659349
references.citation: J Neurosci. 2001 Sep 15;21(18):7143-52
references.pmid: 11549725
references.citation: Neuro Endocrinol Lett. 2002 Aug;23(4):273-80
references.pmid: 12195224
references.citation: Br J Pharmacol. 2008 Feb;153(4):737-50
references.pmid: 18071294
references.citation: Br J Pharmacol. 2010 Aug;160(8):1941-52
references.pmid: 20649592
references.citation: J Neuroendocrinol. 2012 Apr;24(4):681-9
references.pmid: 22340013
references.citation: Nature. 1967 Oct 14;216(5111):173-4
references.pmid: 4862079
references.citation: J Neurosci. 2010 Oct 20;30(42):14213-24
references.pmid: 20962242
references.citation: Eur Biophys J. 2009 Mar;38(3):339-46
references.pmid: 18414844
references.citation: Neuropharmacology. 1997 Sep;36(9):1285-94
references.pmid: 9364483
references.citation: Annu Rev Physiol. 1983;45:129-35
references.pmid: 6847162
references.citation: Mol Pharmacol. 2000 Jul;58(1):82-8
references.pmid: 10860929
references.citation: J Neurosci Methods. 2007 Jul 30;163(2):226-34
references.pmid: 17452053
references.citation: Trends Neurosci. 2006 May;29(5):257-62
references.pmid: 16564580
references.citation: J Clin Invest. 2011 May;121(5):2037-47
references.pmid: 21505260
references.citation: Am J Physiol Regul Integr Comp Physiol. 2006 Jul;291(1):R59-67
references.pmid: 16497814
references.citation: J Biol Chem. 2011 Apr 1;286(13):11370-81
references.pmid: 21292765
references.citation: Prog Brain Res. 2008;170:93-107
references.pmid: 18655875
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 1999 Feb;359(2):102-9
references.pmid: 10048594
references.citation: Nat Neurosci. 2005 Aug;8(8):1078-86
references.pmid: 15995701
references.citation: Clin J Am Soc Nephrol. 2007 Mar;2(2):196-7
references.pmid: 17699405
references.citation: EMBO J. 2006 Nov 1;25(21):5071-82
references.pmid: 17036048
references.citation: J Neurosci. 2003 Feb 15;23(4):1320-8
references.pmid: 12598620
references.citation: Am J Physiol Regul Integr Comp Physiol. 2009 Oct;297(4):R940-9
references.pmid: 19625689
references.citation: J Physiol. 1988 May;399:591-605
references.pmid: 3404469
references.citation: J Neurosci. 2004 Jul 14;24(28):6307-14
references.pmid: 15254086
references.citation: Brain Res. 2005 Feb 9;1034(1-2):40-50
references.pmid: 15713258
references.citation: Neuroscience. 2011 Aug 11;188:1-12
references.pmid: 21575687
references.citation: J Neurochem. 2008 Jun 1;105(6):2330-42
references.pmid: 18315565
references.citation: J Physiol. 2009 Jun 15;587(Pt 12):2887-901
references.pmid: 19403602
references.citation: Physiol Rev. 2001 Oct;81(4):1599-658
references.pmid: 11581498
references.citation: Biochem Biophys Res Commun. 2008 Dec 19;377(3):803-8
references.pmid: 18938136
references.citation: Pflugers Arch. 2005 Sep;450(6):381-9
references.pmid: 15988588
references.citation: J Physiol. 1998 Aug 15;511 ( Pt 1):89-103
references.pmid: 9679166
references.citation: J Gen Physiol. 2011 Oct;138(4):437-52
references.pmid: 21911484
references.citation: J Neuroendocrinol. 2006 Apr;18(4):266-72
references.pmid: 16503921
references.citation: Fed Proc. 1980 Sep;39(11):2889-95
references.pmid: 6997091
references.citation: J Clin Endocrinol Metab. 2008 Jun;93(6):2072-8
references.pmid: 18349067
references.citation: J Hypertens. 1997 May;15(5):545-50
references.pmid: 9170008
references.citation: J Neurochem. 2004 Jul;90(2):359-67
references.pmid: 15228593
references.citation: Br J Pharmacol. 2007 May;151(1):103-14
references.pmid: 17339830
references.citation: Science. 1996 May 3;272(5262):735-8
references.pmid: 8614837